期刊文献+

自拟化瘀降脂汤联合辛伐他汀对高血脂症患者血脂及肝功能指标的影响探析 被引量:3

Effect of Self-made Huayu Jiangzhi Decoction Combined with Simvastatin on Blood Lipids and Liver Function Indexes in Patients with Hyperlipidemia
暂未订购
导出
摘要 目的探讨自拟化瘀降脂汤联合辛伐他汀对高血脂症患者血脂及肝功能指标的影响。方法随机选取2016年8月—2017年8月该院所收治的高血脂症患者120例,随机分为两组,分别为研究组和对照组,每组60例。对照组采用口服辛伐他汀的方法进行治疗,研究组采用给予患者自拟化瘀降脂汤联合辛伐他汀进行治疗并将治疗一段时间后研究组和对照组的综合疗效及血脂水平中LDL-C、HDL-C、TG、TC指标进行对比。结果将研究组与对照组的综合疗效进行对比,治疗期间观察两组患者的血脂水平有无恢复正常指标或明显改善,研究组患者的治疗效果明显优于对照组(χ~2=5.234,P<0.05);将研究组与对照组治疗前后血脂水平中LDL-C、HDL-C、TG、TC进行对比,正常指标变化为TG、TC与LDL-C值较治疗前降低,HDL-C较治疗前升高,研究组患者的血脂水平各指标明显优于对照组(P<0.05)。如对照组患者血脂水平中的TC含量治疗前为(6.75±0.94)mmol/L,治疗后为(5.32±0.42)mmol/L;研究组患者TC含量治疗前为(6.78±0.85)mmol/L,治疗后为(4.26±0.47)mmol/L。结论在治疗高血脂症患者过程当中,自拟化瘀降脂汤联合辛伐他汀的治疗效果理想,有效提高了临床疗效,避免了患者不良反应的发生,并对恢复肝功能有着良好的效果,临床上应当进一步推广应用。 Objective To investigate the effects of self-made Huayu Jiangzhi Decoction combined with simvastatin on blood lipids and liver function in patients with hyperlipidemia. Methods A total of 120 patients with hyperlipidemia admitted to the hospital from August 2016 to August 2017 were convenient randomly divided into two groups, the study group and the control group, with 60 cases in each group. The control group was treated with oral simvastatin. The study group was treated with self-made Huayu Jiangzhi Decoction combined with simvastatin and the combined effect of the study group and the control group and LDL- in the blood lipid level after treatment for a period of time. C, HDL-C, TG, TC indicators for com- parison. Results The comprehensive efficacy of the study group and the control group were compared. During the treatment period, the blood lipid levels of the two groups were observed to return to normal or improved significantly. The treatment effect of the study group was significantly better than that of the control group (χ^2=5.234,P〈0.05). The study group and the control group were compared with LDL-C, HDL-C, TG and TC in the blood lipid levels before and after treatment. The nor- real indicators were changed to TG, TC and LDL-C values before treatment, and HDL-C was compared before treatment. The levels of blood lipids in the study group were significantly higher than those in the control group (P〈0.05). For example, the TC content in the blood lipid level of the control group was (6.75±0.94)mmol/L before treatment and (5.32±0.42)mmol/L after treatment. The TC content of the study group was (6.78±0.85)mmol/L before treatment and (4.26±0.47)mmol/L after treatment. Conclusion In the treatment of patients with hyperlipidemia, the treatment of ttuayu Jiangzhi Decoction combined with simvastatin is effective, effectively improves the clinical efficacy, avoids the occurrence of adverse reactions, and has a good effect on restoring liver function. It should be further promoted and applied clinically.
作者 胡君 王春 杨靖 HU Jun;WANG Chun;YANG Jing(Department of Clinical Laboratory,Friendship Hospital of Urumqi,Urumqi,Xinjiang,830000 China;Deparlment of Clinical Laboratory,Urumqi Hospital of Traditional Chinese Medicine,Urumqi,Xinjiang,830000 China)
出处 《中外医疗》 2018年第26期171-173,共3页 China & Foreign Medical Treatment
关键词 化瘀降脂汤 辛伐他汀 血脂 肝功能 Huayu Jiangzhi Decoction Simvastatin Blood lipids Liver function
  • 相关文献

参考文献9

二级参考文献62

  • 1雷霆雯,许庆忠,吴宁,李红,吴青青.中国苗族CYP2D6*10B基因多态性研究[J].中国公共卫生,2004,20(4):439-440. 被引量:6
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5232
  • 3Cohen J C, Horton J D, Hobbs H H. Human fatty liver disease: old questionsand new insights[J].Science, 2011, 332(6037):1519-1523.
  • 4HESS G, CHANG CL, CHUNG K. Lipid attainment among patients newly treated with lipid-altering drugs [J]. Curr Med Res Opin, 2014,30(9): 1743-1756.
  • 5KAUFMAN AL, SPITZ J, JACOBS M, et al. Evidence for clinical implementation of pharmacogenomics in cardiac drugs [J]. Mayo Clin Proc, 2015,90(6):716-729.
  • 6RAGIA G, KOLOVOU V, TAVRIDOU A, et al. Lack of association of the p450 oxidoreductase * 28 single nucleotide polymorphism with the lipid -lowering effect of statins in hypercholesterolemic patients [J]. Mol Diagn Ther, 2014,18(3) : 323-33l.
  • 7KERR KP, MATE KE, MAGIN PJ, et al. The prevalence of coprescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians [J]. J Clin Pharm Ther, 2014,39(4) :383-389.
  • 8CANESTARO WJ, AUSTIN MA, THUMMEL KE. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review [J]. Genet Med, 2014, 16 (11): 810-819.
  • 9MULDER AB, V AN LIJF HJ, BON MA, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin [J]. Clin Pharmacol Ther, 2001,70 (6) :546-551.
  • 10GEISEL J, KIVIST KT, GRIESE EU, et al. The efficacy of simvastatin is not influenced by CYP2D6 polymorphism [J]. Clin Pharmacol Ther, 2002, 72( 5) : 595-596.

共引文献61

同被引文献23

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部